Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 291

1.

Explaining the aggressiveness of breast cancer in sub-Saharan African patients.

Bravaccini S, Bucchi L, Puccetti M, Ravaioli S, Tumedei MM, Serra P, Masini C, Kahima J, Masalu N, Amadori D.

J Clin Pathol. 2019 Aug 13. pii: jclinpath-2019-206071. doi: 10.1136/jclinpath-2019-206071. [Epub ahead of print] No abstract available.

PMID:
31409610
2.

Female breast cancers (T1-2, N0, M0, HR+, HER2-) with an intermediate genetic-based recurrence risk: a real-world estimate in Italy.

Crocetti E, Ravaioli A, Amadori D, Mancini S, Vattiato R, Giuliani O, Baldacchini F, Falcini F.

Tumori. 2019 May 15:300891619849291. doi: 10.1177/0300891619849291. [Epub ahead of print]

PMID:
31088341
3.

Stemness underpinning all steps of human colorectal cancer defines the core of effective therapeutic strategies.

Visioli A, Giani F, Trivieri N, Pracella R, Miccinilli E, Cariglia MG, Palumbo O, Arleo A, Dezi F, Copetti M, Cajola L, Restelli S, Papa V, Sciuto A, Latiano TP, Carella M, Amadori D, Gallerani G, Ricci R, Alfieri S, Pesole G, Vescovi AL, Binda E.

EBioMedicine. 2019 Jun;44:346-360. doi: 10.1016/j.ebiom.2019.04.049. Epub 2019 May 2.

4.

Ten-year experience of the multidisciplinary Osteoncology Center.

Bongiovanni A, Recine F, Fausti V, Foca F, Casadei R, Falasconi MC, Oboldi D, Sansoni E, Fabbri L, Micheletti S, Severi S, Matteucci F, Zavoiu V, Mercatali L, Amadori D, Ibrahim T.

Support Care Cancer. 2019 Sep;27(9):3395-3402. doi: 10.1007/s00520-019-4635-5. Epub 2019 Jan 16.

PMID:
30649614
5.

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.

Pietri E, Massa I, Bravaccini S, Ravaioli S, Tumedei MM, Petracci E, Donati C, Schirone A, Piacentini F, Gianni L, Nicolini M, Campadelli E, Gennari A, Saba A, Campi B, Valmorri L, Andreis D, Fabbri F, Amadori D, Rocca A.

Oncologist. 2019 Jun;24(6):743-e205. doi: 10.1634/theoncologist.2018-0243. Epub 2018 Dec 27.

6.

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.

Conteduca V, Gurioli G, Rossi L, Scarpi E, Lolli C, Schepisi G, Farolfi A, De Lisi D, Gallà V, Burgio SL, Menna C, Amadori A, Losi L, Amadori D, Costi MP, De Giorgi U.

BMC Cancer. 2018 Dec 19;18(1):1267. doi: 10.1186/s12885-018-5180-1.

7.

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab.

Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P.

Cancer Manag Res. 2018 Nov 14;10:5659-5666. doi: 10.2147/CMAR.S181570. eCollection 2018.

8.

Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age.

Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.

Endocr Connect. 2018 Dec 1. pii: EC-18-0478.R1. doi: 10.1530/EC-18-0478. [Epub ahead of print]

9.

Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial.

Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassineti GL, Amadori D, Passardi A.

Onco Targets Ther. 2018 Aug 29;11:5261-5268. doi: 10.2147/OTT.S166614. eCollection 2018.

10.

Dried Blood and Serum Spots As A Useful Tool for Sample Storage to Evaluate Cancer Biomarkers.

Mercatali L, Serra P, Miserocchi G, Spadazzi C, Liverani C, De Vita A, Marisi G, Bongiovanni A, Recine F, Pangan A, Masalu N, Ibrahim T, Amadori D.

J Vis Exp. 2018 Jun 11;(136). doi: 10.3791/57113.

PMID:
29939179
11.

Chemotherapy and palliative care near end-of life: examining the appropriateness at a cancer institute for colorectal cancer patients.

Massa I, Nanni O, Foca F, Maltoni M, Derni S, Gentili N, Frassineti GL, Casadei Gardini A, Valgiusti M, Amadori D, Prati E, Altini M, Gallegati D, Sansoni E.

BMC Palliat Care. 2018 Jun 19;17(1):86. doi: 10.1186/s12904-018-0339-8.

12.

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?

Bronte G, Bravaccini S, Ravaioli S, Puccetti M, Scarpi E, Andreis D, Tumedei MM, Sarti S, Cecconetto L, Pietri E, De Simone V, Maltoni R, Bonafè M, Amadori D, Rocca A.

Transl Oncol. 2018 Aug;11(4):950-956. doi: 10.1016/j.tranon.2018.05.006. Epub 2018 Jun 18.

13.

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma.

De Vita A, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Recine F, Bongiovanni A, Pieri F, Cavaliere D, Fausti V, Amadori D, Ibrahim T.

J Vis Exp. 2018 Apr 11;(134). doi: 10.3791/56767.

PMID:
29708525
14.

Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?

Bravaccini S, Ravaioli S, Amadori D, Scarpi E, Puccetti M, Rocca A, Tumedei MM, Masalu N, Kahima J, Pangan A, Faustine L, Farolfi A, Maltoni R, Bonafè M, Serra P, Bronte G.

Front Endocrinol (Lausanne). 2018 Mar 29;9:137. doi: 10.3389/fendo.2018.00137. eCollection 2018.

15.

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

Bronte G, Rocca A, Ravaioli S, Puccetti M, Tumedei MM, Scarpi E, Andreis D, Maltoni R, Sarti S, Cecconetto L, Fedeli A, Pietri E, De Simone V, Asioli S, Amadori D, Bravaccini S.

BMC Cancer. 2018 Mar 27;18(1):348. doi: 10.1186/s12885-018-4239-3.

16.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.

Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29482983
17.

Myxofibrosarcoma primary cultures: molecular and pharmacological profile.

De Vita A, Recine F, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Casadei R, Bongiovanni A, Pieri F, Riva N, Amadori D, Ibrahim T.

Ther Adv Med Oncol. 2017 Dec;9(12):755-767. doi: 10.1177/1758834017737472. Epub 2017 Oct 28.

18.

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.

Ulivi P, Canale M, Passardi A, Marisi G, Valgiusti M, Frassineti GL, Calistri D, Amadori D, Scarpi E.

Int J Mol Sci. 2018 Jan 20;19(1). pii: E307. doi: 10.3390/ijms19010307.

19.

Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Vannini I, Wise PM, Challagundla KB, Plousiou M, Raffini M, Bandini E, Fanini F, Paliaga G, Crawford M, Ferracin M, Ivan C, Fabris L, Davuluri RV, Guo Z, Cortez MA, Zhang X, Chen L, Zhang S, Fernandez-Cymering C, Han L, Carloni S, Salvi S, Ling H, Murtadha M, Neviani P, Gitlitz BJ, Laird-Offringa IA, Nana-Sinkam P, Negrini M, Liang H, Amadori D, Cimmino A, Calin GA, Fabbri M.

Nat Commun. 2018 Jan 8;9(1):160. doi: 10.1038/s41467-017-02485-1.

20.

Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.

De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, Bongiovanni A, Pieri F, Casadei R, Riva N, Fausti V, Amadori D, Ibrahim T.

Int J Mol Sci. 2017 Dec 8;18(12). pii: E2662. doi: 10.3390/ijms18122662.

Supplemental Content

Loading ...
Support Center